Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NBIX Stock Forecast 2025-2026
$124.88
Current Price
$12.40B
Market Cap
Buy 22
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to NBIX Price Targets
+53.7%
To High Target of $192.00
+28.1%
To Median Target of $160.00
-7.9%
To Low Target of $115.00
NBIX Price Momentum
-0.1%
1 Week Change
+1.7%
1 Month Change
-4.6%
1 Year Change
-8.5%
Year-to-Date Change
-21.0%
From 52W High of $157.98
+48.3%
From 52W Low of $84.23
📊 TOP ANALYST CALLS
Did NBIX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Neurocrine is one of their latest high-conviction picks.
Latest NBIX Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, NBIX has a bullish consensus with a median price target of $160.00 (ranging from $115.00 to $192.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $124.88, the median forecast implies a 28.1% upside. This outlook is supported by 22 Buy, 3 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Evan Seigerman at BMO Capital, suggesting a 7.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NBIX Analyst Ratings
22
Buy
3
Hold
0
Sell
NBIX Price Target Range
Low
$115.00
Average
$160.00
High
$192.00
Current: $124.88
Latest NBIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NBIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $145.00 |
| May 6, 2025 | Piper Sandler | David Amsellem | Overweight | Reiterates | $154.00 |
| May 6, 2025 | UBS | Ashwani Verma | Buy | Maintains | $152.00 |
| May 6, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $165.00 |
| May 6, 2025 | Needham | Ami Fadia | Buy | Maintains | $139.00 |
| May 6, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $160.00 |
| May 6, 2025 | BMO Capital | Evan Seigerman | Market Perform | Maintains | $115.00 |
| May 6, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $145.00 |
| Apr 28, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $158.00 |
| Apr 24, 2025 | Evercore ISI Group | Cory Kasimov | Outperform | Maintains | $185.00 |
| Apr 22, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $168.00 |
| Apr 15, 2025 | Needham | Ami Fadia | Buy | Upgrade | $138.00 |
| Apr 14, 2025 | RBC Capital | Brian Abrahams | Outperform | Upgrade | $137.00 |
| Apr 4, 2025 | UBS | Ashwani Verma | Buy | Maintains | $137.00 |
| Mar 26, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $184.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $150.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $185.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $185.00 |
| Feb 10, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $163.00 |
| Feb 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $185.00 |
Neurocrine Biosciences Inc. (NBIX) Competitors
The following stocks are similar to Neurocrine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neurocrine Biosciences Inc. (NBIX) Financial Data
Neurocrine Biosciences Inc. has a market capitalization of $12.40B with a P/E ratio of 42.5x. The company generates $2.41B in trailing twelve-month revenue with a 12.7% profit margin.
Revenue growth is +11.1% quarter-over-quarter, while maintaining an operating margin of +4.1% and return on equity of +12.4%.
Valuation Metrics
Market Cap
$12.40B
Enterprise Value
$11.86B
P/E Ratio
42.5x
PEG Ratio
20.2x
Price/Sales
5.1x
Growth & Margins
Revenue Growth (YoY)
+11.1%
Gross Margin
+98.4%
Operating Margin
+4.1%
Net Margin
+12.7%
EPS Growth
-81.8%
Financial Health
Cash/Price Ratio
+7.6%
Current Ratio
3.1x
Debt/Equity
19.4x
ROE
+12.4%
ROA
+8.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Neurocrine Biosciences Inc. (NBIX) Business Model
About Neurocrine Biosciences Inc.
What They Do
Develops treatments for neurological and endocrine disorders.
Business Model
Neurocrine Biosciences generates revenue by discovering, developing, and commercializing innovative biopharmaceuticals, with a focus on unmet medical needs in neurological and endocrine-related disorders. Its key products, such as Ingrezza and Orilissa, represent successful applications of their research, with ongoing partnerships enhancing their market reach.
Additional Information
Founded in 1992 and headquartered in San Diego, California, the company has a strong pipeline targeting conditions like Parkinson’s disease and congenital adrenal hyperplasia, positioning itself as a leader in biopharmaceutical innovation and patient care.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,800
CEO
Mr. Kyle W. Gano Ph.D.
Country
United States
IPO Year
1996
Website
www.neurocrine.comNeurocrine Biosciences Inc. (NBIX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Sector ETF report for XBI
Jun 12, 2025
By Zacks Equity Research
Sector ETF
Latest News
Quick Summary
Neurocrine Biosciences appointed Lewis Choi as Chief Information Officer, effective June 9, 2025, to lead its technology initiatives and strategic direction.
Why It Matters
The appointment of Lewis Choi as CIO may enhance Neurocrine's tech strategy, potentially leading to improved efficiencies and innovations, impacting future growth and profitability.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Neurocrine Biosciences announced positive results from the KINECT-PRO study, showing INGREZZA significantly improves functioning in tardive dyskinesia patients from Week 4 to Week 24.
Why It Matters
Positive results from the KINECT-PRO study for INGREZZA indicate strong efficacy in treating tardive dyskinesia, potentially increasing Neurocrine Biosciences' market value and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Nxera Pharma (TSE 4565) announced a $15 million payment from Neurocrine Biosciences after the first patient was dosed in a Phase 3 trial for schizophrenia treatment, to be recognized in Q2 2025.
Why It Matters
Nxera Pharma's Phase 3 trial progress for NBI-1117568 and the $15 million revenue recognition could enhance investor confidence and impact stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in the Medical - Drugs sector may find Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX) appealing options for potential value investing.
Why It Matters
The comparison between Catalyst Pharmaceutical and Neurocrine Biosciences highlights potential investment opportunities, guiding value investors toward stock selection in the Medical - Drugs sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Neurocrine Biosciences presented positive Phase 2 data for NBI-1117568, showing significant symptom improvement in schizophrenia and highlighting safety and tolerability.
Why It Matters
Positive Phase 2 results for NBI-1117568 indicate potential market advantage in treating schizophrenia, enhancing Neurocrine Biosciences' growth prospects and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Nxera Pharma (TSE 4565) noted that Neurocrine Biosciences presented positive Phase 2 data for NBI-1117568 in schizophrenia at the ASCP 2025 Annual Meeting.
Why It Matters
Positive Phase 2 data for NBI-1117568 could enhance Neurocrine's stock value and market position in schizophrenia treatment, potentially impacting Nxera's partnership and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NBIX Stock
What is Neurocrine Biosciences Inc.'s (NBIX) stock forecast for 2025?
Based on our analysis of 33 Wall Street analysts, Neurocrine Biosciences Inc. (NBIX) has a median price target of $160.00. The highest price target is $192.00 and the lowest is $115.00.
Is NBIX stock a good investment in 2025?
According to current analyst ratings, NBIX has 22 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $124.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NBIX stock?
Wall Street analysts predict NBIX stock could reach $160.00 in the next 12 months. This represents a 28.1% increase from the current price of $124.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurocrine Biosciences Inc.'s business model?
Neurocrine Biosciences generates revenue by discovering, developing, and commercializing innovative biopharmaceuticals, with a focus on unmet medical needs in neurological and endocrine-related disorders. Its key products, such as Ingrezza and Orilissa, represent successful applications of their research, with ongoing partnerships enhancing their market reach.
What is the highest forecasted price for NBIX Neurocrine Biosciences Inc.?
The highest price target for NBIX is $192.00 from at , which represents a 53.7% increase from the current price of $124.88.
What is the lowest forecasted price for NBIX Neurocrine Biosciences Inc.?
The lowest price target for NBIX is $115.00 from Evan Seigerman at BMO Capital, which represents a -7.9% decrease from the current price of $124.88.
What is the overall NBIX consensus from analysts for Neurocrine Biosciences Inc.?
The overall analyst consensus for NBIX is bullish. Out of 33 Wall Street analysts, 22 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $160.00.
How accurate are NBIX stock price projections?
Stock price projections, including those for Neurocrine Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 1:31 PM UTC